Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Melanoma and other skin tumours

4466 - Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial

Date

11 Sep 2017

Session

Melanoma and other skin tumours

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Surgical Oncology;  Radiation Oncology;  Melanoma

Presenters

Elisa Rozeman

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

E.A. Rozeman1, W. Prevoo2, M.A.J. Meier2, K. Sikorska3, B.A. van de Wiel4, A. Broeks5, H. van Tinteren3, E. Kapiteijn6, J.V. Thienen1, J.B. Haanen1, C.U. Blank1

Author affiliations

  • 1 Medical Oncology Department, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 2 Department Of Radiology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 3 Department Of Biometrics, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 4 Department Of Pathology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 5 Core Facility Molecular Pathology & Biobanking, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 6 Department Of Clinical Oncology, LUMC, Leiden/NL
More

Resources

Abstract 4466

Background

After enucleation or radiotherapy of the primary lesion, 50% of uveal melanoma (UM) patients develop distant metastases. In contrast to cutaneous melanoma, targeted therapies and checkpoint inhibitors failed to improve overall survival (OS) in UM. Chemoembolization or intrahepatic artery perfusion improved local control, but failed to show OS benefit. The anti-CTLA-4 antibody ipilimumab (IPI), showed limited clinical activity in UM, thus combination therapies may be required. Preclinical experiments in a murine melanoma model indicated that additional radiofrequency ablation(RFA) enhanced antigen presentation and induced durable responses.

Methods

We therefore have set-up a phase 1b/2 study to assess safety and efficacy of the combination of RFA and IPI in UM patients with at least 2 unresectable liver lesions. In the phase 1b part patients underwent RFA of one liver lesion and received 4 courses IPI 0,3mg/kg, 3mg/kg or 10mg/kg q3wk in a 3 + 3 design. Primary endpoint of the phase 1b part was safety in terms of dose limiting toxicities per cohort to define the recommended phase 2 dose(RP2D). Primary endpoints of the phase 2 part were confirmed objective response rate (ORR) and disease control rate (DCR) according to RECIST 1.1 (only non-RFA lesions), secondary endpoints were progression free survival (PFS) and OS.

Results

IPI 10mg/kg + RFA was defined as the RP2D. After 19 patients had been treated, the study was amended to adjust the RP2D to IPI 3mg/kg + RFA, because 9 patients (47%) had developed grade 3 colitis. In the 3mg/kg IPI + RFA cohort also 19 patients have been treated, and baseline characteristics were balanced between the cohorts. Treatment related grade ≥3 AEs were seen in 53% of patients in the 10mg/kg cohort versus 32% in the 3mg/kg cohort. No confirmed objective responses were observed; the confirmed DCR was 21% in the 10mg/kg cohort and 11% in the 3mg/kg cohort. Median PFS was 2.8 months and was comparable for both groups, median OS was 13.6 months for the 10mg/kg cohort versus 9.5 months for the 3mg/kg cohort (p = 0.23).

Conclusions

The combination of IPI 3mg/kg +RFA was safe but showed limited clinical activity in UM. However, overall survival seems to be longer compared to other study cohorts of UM patients, especially in the IPI 10mg/kg cohort.

Clinical trial identification

EudraCT Number: 2011-004200-38

Legal entity responsible for the study

NKI-AVL

Funding

Bristol-Myers Squibb

Disclosure

J.V. Thienen: Advisory board: MSD, Bristol-Myers Squibb. J.B. Haanen: Advisory role: Bristol-Myers Squibb. MSD, Pfizer, Roche, Novartis, Neon Therapeutics Research grants: Bristol-Myers Squibb, MSD, GSK. C.U. Blank: Advisory board: Bristol-Myers Squibb, MSD, Novartis, GSK, Pfizer, Lilly, Roche Research grant: Bristol-Myers Squibb, Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.